Neurocrine to Buy Soleno, Nabbing Drug for Relentless Hunger Disorder

2026-04-06 | original

read original more articles

The deal, valued at $2.9 billion, will expand Neurocrine’s endocrinology and rare-disease portfolio.

Explore topics: neurocrine soleno drug endocrinology rare-disease